Francesca Bruschi

Dr. Francesca Bruschi

Medical University of Vienna
orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 April 2017 in Hepatology
Verified
Journal Article
Closed access
Francesca BruschiFrancesca Bruschi
Francesca Bruschi
TCThierry Claudel
Thierry Claudel
MTMatteo Tardelli
Matteo Tardelli
ACAlessandra Caligiuri
Alessandra Caligiuri
TSThomas Michael Stulnig
Thomas Michael Stulnig
MTMichael Trauner
Michael Trauner

1 November 2017 in Hepatic Medicine: Evidence and Research
Verified
Journal Article
Open access
PDF file
Francesca BruschiFrancesca Bruschi
Francesca Bruschi
MTMatteo Tardelli
Matteo Tardelli
TCThierry Claudel
Thierry Claudel
MTMichael Trauner
Michael Trauner
A single-nucleotide polymorphism occurring in the sequence of the human patatin-like phospholipase domain-containing 3 gene (PNPLA3), known as I148M variant, is one of the best characterized and deeply investigated variants in several clinical scenarios, because of its tight correlation with increased risk for developing hepatic steatosis and more aggressive part of the disease spectrum, such as nonalcoholic steatohepatitis, advanced fibrosis and cirrhosis. Further, the I148M variant is positively associated with alcoholic liver diseases, chronic hepatitis C–related cirrhosis and hepatocellular carcinoma. The native gene encodes for a protein that has not yet a fully defined role in liver lipid metabolism and, according to recent observations, seems to be divergently regulated among distinct liver cells type, such as hepatic stellate cells. Therefore, the aim of this review is to collect the latest data regarding PNPLA3 expression in human liver and to analyze the impact of its genetic variant in human hepatic pathologies. Moreover, a description of the current biochemical and metabolic data pertaining to PNPLA3 function in both animal models and in vitro studies is summarized to allow a better understanding of the relevant pathophysiological role of this enzyme in the progression of hepatic diseases.

1 April 2020 in Hepatology
Verified
Journal Article
Open access
PDF file
MTMatteo Tardelli
Matteo Tardelli
Francesca BruschiFrancesca Bruschi
Francesca Bruschi
MTMichael Trauner
Michael Trauner
Intracellular lipolysis is an enzymatic pathway responsible for the catabolism of triglycerides (TGs) that is complemented by lipophagy as the autophagic breakdown of lipid droplets. The hydrolytic cleavage of TGs generates free fatty acids (FFAs), which can serve as energy substrates, precursors for lipid synthesis, and mediators in cell signaling. Despite the fundamental and physiological importance of FFAs, an oversupply can trigger lipotoxicity with impaired membrane function, endoplasmic reticulum stress, mitochondrial dysfunction, cell death, and inflammation. Conversely, impaired release of FFAs and other lipid mediators can also disrupt key cellular signaling functions that regulate metabolism and inflammatory processes. This review will focus on specific functions of intracellular lipases in lipid partitioning, covering basic and translational findings in the context of liver disease. In addition, the clinical relevance of genetic mutations in human disease and potential therapeutic opportunities will be discussed.

15 July 2019 in Hepatology Communications
Verified
Journal Article
Open access
PDF file
Francesca BruschiFrancesca Bruschi
Francesca Bruschi
TCThierry Claudel
Thierry Claudel
MTMatteo Tardelli
Matteo Tardelli
PSPatrick Starlinger
Patrick Starlinger
FMFabio Marra
Fabio Marra
MTMichael Trauner
Michael Trauner
The patatin‐like phospholipase domain‐containing protein 3 (PNPLA3) I148M variant predisposes to hepatic steatosis and progression to advanced liver injury with development of fibrosis, cirrhosis, and cancer. Hepatic stellate cells (HSCs) drive the wound healing response to chronic injury, and lack of liver X receptor (LXR) signaling exacerbates liver fibrogenesis by impairing HSC cholesterol homeostasis. However, the contribution of the I148M variant to this process is still unknown. We analyzed LXR expression and transcriptional activity in primary human HSCs and overexpressing LX‐2 cells according to PNPLA3 genotype (wild type [WT] versus I148M). Here we demonstrate that LXRα protein increased whereas LXR target gene expression decreased during in vitro activation of primary human HSCs. Notably, LXRα levels and signaling were reduced in primary I148M HSCs compared to WT, as displayed by decreased expression of LXR target genes. Moreover, reduced expression of cholesterol efflux and enzymes generating oxysterols was associated with higher total and free cholesterol accumulation whereas endogenous cholesterol synthesis and uptake were diminished in I148M HSCs. Luciferase assays on LXR response element confirmed decreased LXR transcriptional activity in I148M HSCs; in contrast the synthetic LXR agonist T0901317 replenished LXR functionality, supported by adenosine triphosphate‐binding cassette subfamily A member 1 (ABCA1) induction, and reduced collagen1α1 and chemokine (C‐C motif) ligand 5 expression. Conversely, the peroxisome proliferator‐activated receptor gamma (PPARγ) agonist rosiglitazone had only partial effects on the LXR target gene ABCA1, and neither diminished expression of proinflammatory cytokines nor increased de novo lipogenic genes in I148M HSCs. Conclusion: As a consequence of reduced PPARγ activity, HSCs carrying I148M PNPLA3 show impaired LXR signaling, leading to cholesterol accumulation. The use of a specific LXR agonist shows beneficial effects for diminishing sustained HSC activation and development of liver fibrogenesis.

1 July 2019 in Journal of Lipid Research
Verified
Journal Article
Open access
PDF file
MTMatteo Tardelli
Matteo Tardelli
Francesca BruschiFrancesca Bruschi
Francesca Bruschi
TCThierry Claudel
Thierry Claudel
CFClaudia D. Fuchs
Claudia D. Fuchs
NANicole Auer
Nicole Auer
MTMichael Trauner
Michael Trauner
Matteo Tardelli, Francesca V. Bruschi, Thierry Claudel, Claudia D. Fuchs, Nicole Auer, Victoria Kunczer, Tatjana Stojakovic, Hubert Scharnagl, Aida Habib, Gernot F. Grabner, Robert Zimmermann, Sophie Lotersztajn, Michael Trauner

1 March 2020 in Liver International
Verified
Journal Article
Open access
Francesca BruschiFrancesca Bruschi
Francesca Bruschi
MTMatteo Tardelli
Matteo Tardelli
MHMerima Herac
Merima Herac
TCThierry Claudel
Thierry Claudel
MTMichael Trauner
Michael Trauner
Background and Aims: The genetic PNPLA3 polymorphism I148M has been extensively associated with higher risk for development and progression of NAFLD towards NASH.Methods: PNPLA3 and α‐SMA expression were quantified in liver biopsies collected from NASH patients (n = 26) with different fibrosis stages and PNPLA3 genotypes. To study the potential mechanisms driving PNPLA3 expression during NASH progression towards fibrosis, hepatocytes and hepatic stellate cells (HSCs) were cultivated in low and high glucose medium. Moreover, hepatocytes were treated with increasing concentrations of palmitic acid alone or in combination with glucose. Conditioned media were collected from challenged hepatocytes to stimulate HSCs.Results: Tissue expression of PNPLA3 was significantly enhanced in biopsies of patients carrying the I148M polymorphism compared to wild type (WT). In NASH biopsies, PNPLA3 significantly correlated with fibrosis stage and α‐SMA levels independently of PNPLA3 genotype. In line, PNPLA3 expression was higher in α‐SMA positive cells. Low glucose increased PNPLA3 in HSCs, whereas high glucose induced PNPLA3 and de‐novo lipogenesis‐related genes expression in hepatocytes. Palmitic acid induced fat accumulation and cell stress markers in hepatocytes, which could be counteracted by oleic acid. Conditioned media collected from lipotoxic challenged hepatocytes markedly induced PNPLA3 mRNA and protein levels, fibrogenic and autophagic markers and promoted migration in HSCs. Notably, conditioned media collected from hepatocytes cultivated with both glucose and palmitic acid exacerbated HSCs migration, PNPLA3 and fibrogenic gene expression, promoting release of cytokines from HSCs.Conclusions: Collectively, our observations uncover the diverse metabolic regulation of PNPLA3 among different hepatic cell populations and support its relation to fibrosis progression.